Mark Cuban Cost Plus Manufacturing and Compounding, LLC, Dallas, TX

Is Mark Cuban Cost Plus Manufacturing and Compounding, LLC an FDA-registered 503B outsourcing facility?

Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Mark Cuban Cost Plus Manufacturing and Compounding, LLC in Dallas, TX, first registered Nov 2, 2022 and most recently registered Dec 14, 2024. FDA lists its last inspection as Sep 30, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Open”.

FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.

Location on FDA’s list
Dallas, TX
Initial registration
Nov 2, 2022
Most recent registration
Dec 14, 2024
Last inspection
Sep 30, 2026
Form 483 issued at last inspection
Yes
Recall after last inspection
No
Action on last inspection
Open
Intends to compound sterile drugs from bulk substances
Yes
Earlier inspections
FDA notes that an earlier inspection led to a Form 483, warning letter or other action

FDA inspections and actions on record

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Mark Cuban Cost Plus Manufacturing and Compounding LLC, Dallas, TX, a 503B facility, with 3 listed actions, including 1 Form 483 (2024 to 2025).

Document
Jun 5, 2025FMD-145 letterFMD-145 Letter (06/05/2025)Not linked by FDA
Mar 26, 2025Regulatory meetingRegulatory Meeting (03/26/2025)Not linked by FDA
Sep 6, 2024Form 483483 Issued 09/06/2024FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Mark Cuban Cost Plus Manufacturing and Compounding LLC, Dallas, TX (FEI number 3024611767), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Sep 6, 2024Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30246117671248588

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 7 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 26, 2024 to Sep 6, 2024: 7 observations

Firm on the cover
Mark Cuban Cost Plus Manufacturing and Compounding LLC, 3015 Taylor St, Dallas, TX 75 226-1911
FEI number
3024611767
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75 202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.

Specifically,

A. Your firm's sterile filling technicians was observed entering and leaving different ISO 7 classified areas (storage closet, hallway, Sampling/Weighing/Dispensing Room Formulation and Filling Rooms which contain the ISO 5 <Redacted B4>. Filling along with <Redacted B4> performing tasks without adequately disinfecting their stenle gloves adequate frequency to prevent potential contamination as written in your firm's procedure, Aseptic Sterile Drug Processing (Aseptic Technique), DAL-SOP-0227, Rev. 1.0, section Glove Management, sub-sections 8.14 -8.19.

B Your firm sterile filling technician was observed utilizing poor technique putting on sterile gloves <Redacted B4> within ISO 5 <Redacted B4> prior to the preparation of the <Redacted B4> environmental monitoring strip into the holder during the production of Epinephrine Inj ection, USP 5mg/5mL (lmg/lmL), Lot # <Redacted B4> , Actual Qty. <Redacted B4> vials.

C. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable construction to facilitate cleaning, maintenance, and proper operations.

Specifically, your firm's ISO 7 Filling Room (RM 034) containing your ISO 5 <Redacted B4>Filling <Redacted B4> is designed with exposed sprinkler heads within the room ceiling preventmg aaequate cleaning and can be a source of contamination.

Observation 3

Equipment and utensils are not cleaned and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, your firm failed to clean and disinfect laptop computers and desktop computer keyboards used in the production of sterile drug products within your firm's ISO 7 classified cleanroom areas (Sampling/Weighing/Dispensing Room (RM 039); Formulation Room (RM 033); and Filling Room (RM 034)) to prevent possible contamination of drug products.

Observation 4

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically, your firm's quality unit fail to adequately implement your firm's procedure, DAL-SOP-0032, Deviation Procedure. For example, on 8/26/2024, after becoming aware of a power failure within your facility, your firm failed to initiate a deviation to document the event and conduct an impact assessment of facility equipment and finished drug products along with components. For example, during a review of the firm's <Redacted B4> system data that control and monitors temperature, relate humidity, and differential pressure, we found differential pressures within the ISO 7 cleanrooms (Sampling/

Weighing/ Dispensing Room, Formulation and Filling Room) were impacted on the 8/26/2024 date between 7:58 am -8: 11 am. The differential pressure was below the minimum of <Redacted B4> for greater than <Redacted B4> .Your firm management reported an action limit specification of <Redacted B4> sustained below the documented specification. Your firm was unaware of this impact prior to this inspection.

Observation 5

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, your firm's environmental monitoring program fail to include viable air and surface monitoring sampling in areas of operations most prone to contamination within the ISO 7 Filling Room (RM 0034) that contain the ISO 5 <Redacted B4>. For example, firm fail to monitor ISO 5 <Redacted B4> handles, table surface used to hold components for <Redacted B4> System, and stainless-steel racks used to hold logbooks and <Redacted B4> components.

Observation 6

Labeling

1. The container of your outsourcing facility's miglustat suspension drug product did not include information required by section 503B(a)(I0)(B). Specifically, your container did not include the following information.

a. Information to facilitate adverse event reporting www.fda.gov/medwatch and 1800FDA 1088 <http:/ /www.fda.gov/medwatch%20and%201800FDA1088>;

b. Directions for use, including, as appropriate, dosage and administration.

2. The label of your outsourcing facility's miglustat suspension drug product does not include information required by section 503B(a)(I0)(A). Specifically, the following information is not found on your miglustat suspension bottle label:

infonnation required by section 503B(a)(I0)(A). Specifically, the following info1mation is not found on your miglustat suspension bottle label:

a. A list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient. Specifically, the Miglustat 100 mg/mL suspension bottle label is missing the "quantity or proportion " of the following ingredients: glyceryl distearate, polyglyceiyl-3 oleate, medium-chain triglycerides.

Observation 7

PRODUCT REPORTING

I . Your outsourcing facility did not submit a report to FDA at the time of initial registration on November 2, 2022, as required for an outsourcing facility that registers with FDA under section 503B.

GLP-1 records in this index

No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Mark Cuban Cost Plus Manufacturing and Compounding, LLC). That is not a finding beyond this index’s search.

The Mark Cuban Cost Plus Manufacturing and Compounding, LLC pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.